TransCode Therapeutics Inc [NASDAQ: RNAZ] gained 21.11% on the last trading session, reaching $14.8 price per share at the time.
TransCode Therapeutics Inc represents 0.83 million in outstanding shares, while the company has a total market value of $12.34 million with the latest information. RNAZ stock price has been found in the range of $13.182 to $20.99.
If compared to the average trading volume of 87.88K shares, RNAZ reached a trading volume of 7484288 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about TransCode Therapeutics Inc [RNAZ]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RNAZ shares is $280.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RNAZ stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 2.01, with the Price to Cash per share for the same quarter was set at 8.84.
Trading performance analysis for RNAZ stock
TransCode Therapeutics Inc [RNAZ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 39.49. With this latest performance, RNAZ shares gained by 32.74% in over the last four-week period, additionally plugging by 36.23% over the last 6 months – not to mention a drop of -84.32% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RNAZ stock in for the last two-week period is set at 76.10, with the RSI for the last a single of trading hit 1.65, and the three-weeks RSI is set at 1.22 for TransCode Therapeutics Inc [RNAZ]. The present Moving Average for the last 50 days of trading for this stock 10.85, while it was recorded at 11.99 for the last single week of trading, and 49.11 for the last 200 days.
TransCode Therapeutics Inc (RNAZ) Capital Structure & Debt Analysis
According to recent financial data for TransCode Therapeutics Inc. ( RNAZ), the Return on Equity (ROE) stands at -658.62%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -375.82%, reflecting the company’s efficiency in generating profits from its assets. Additionally, TransCode Therapeutics Inc’s Return on Invested Capital (ROIC) is -400.14%, showcasing its effectiveness in deploying capital for earnings.
TransCode Therapeutics Inc (RNAZ) Efficiency & Liquidity Metrics
Based on TransCode Therapeutics Inc’s (RNAZ) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
TransCode Therapeutics Inc (RNAZ) Efficiency & Liquidity Metrics
From an operational efficiency perspective, TransCode Therapeutics Inc. (RNAZ) effectively leverages its workforce, generating an average of -$3514285.71 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.27% and a Quick Ratio of 5.27%, indicating strong ability to cover short-term liabilities.
TransCode Therapeutics Inc [RNAZ]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, TransCode Therapeutics Inc posted -600.6/share EPS, while the average EPS was predicted by analysts to be reported at -25872.02/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25271.42. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RNAZ.
An analysis of Institutional ownership at TransCode Therapeutics Inc [RNAZ]
There are presently around $4.43%, or 4.44%% of RNAZ stock, in the hands of institutional investors.
